Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Severe acute respiratory virus syndrome coronavirus 2 (SARS-CoV-2) was responsible for coronavirus disease (COVID-19) pandemic, which resulted in global health care crisis. As patients recovered from COVID-19 infection, hair loss was increasingly observed as a distressing symptom. We conducted a prospective cross-sectional study of patients presenting with post COVID-19 hair loss between July to December 2021 at a tertiary care centre in north India. Detailed history, clinical examination, trichoscopy and biochemical tests were performed and recorded. COVID-19 disease severity was assessed based on the duration of COVID-19 infection and place of management (home or hospitalized). The study included 120 patients with mean age being 39.6 years. There was female preponderance. Majority of the patients (87%) were treated at home and 43.3% had COVID-19 infection for >2 weeks. Mean visual analog scale (VAS) score for stress was 5.25. Vitamin D deficiency was present in 56.7% and low ferritin in 30% of cases. Mean time of onset of hair loss post COVID-19 was 49 days. Patients mainly presented with diffuse (72.4%) and patterned hair loss (31.6%). Trichodynia was present in 15.8% of cases. The degree of hair loss was severe in 55.8% of the subjects, predominantly in older age group and females. Positive hair pull test was seen in 65% of patients. Most common trichoscopic features included single hair follicles’ (81.7%) and vellus hair >10% (60%). Trichoscopy can aid in unmasking co-existing patterned hair loss in patients presenting clinically with diffuse hair loss. Patients with COVID-19 infection for > 2 weeks had significantly more severe hair loss and VAS score. Trichoscopic findings of vellus hair >10% and empty hair follicles were more frequent in patients who were hospitalized for COVID-19 infection.
Severe acute respiratory virus syndrome coronavirus 2 (SARS-CoV-2) was responsible for coronavirus disease (COVID-19) pandemic, which resulted in global health care crisis. As patients recovered from COVID-19 infection, hair loss was increasingly observed as a distressing symptom. We conducted a prospective cross-sectional study of patients presenting with post COVID-19 hair loss between July to December 2021 at a tertiary care centre in north India. Detailed history, clinical examination, trichoscopy and biochemical tests were performed and recorded. COVID-19 disease severity was assessed based on the duration of COVID-19 infection and place of management (home or hospitalized). The study included 120 patients with mean age being 39.6 years. There was female preponderance. Majority of the patients (87%) were treated at home and 43.3% had COVID-19 infection for >2 weeks. Mean visual analog scale (VAS) score for stress was 5.25. Vitamin D deficiency was present in 56.7% and low ferritin in 30% of cases. Mean time of onset of hair loss post COVID-19 was 49 days. Patients mainly presented with diffuse (72.4%) and patterned hair loss (31.6%). Trichodynia was present in 15.8% of cases. The degree of hair loss was severe in 55.8% of the subjects, predominantly in older age group and females. Positive hair pull test was seen in 65% of patients. Most common trichoscopic features included single hair follicles’ (81.7%) and vellus hair >10% (60%). Trichoscopy can aid in unmasking co-existing patterned hair loss in patients presenting clinically with diffuse hair loss. Patients with COVID-19 infection for > 2 weeks had significantly more severe hair loss and VAS score. Trichoscopic findings of vellus hair >10% and empty hair follicles were more frequent in patients who were hospitalized for COVID-19 infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.